| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-01-07 | Philips (The Netherlands) Banyan Biomarkers (US - CA) | handheld blood test | mild traumatic brain injury (TBI) | development commercialisation |
CNS diseases - Neurological diseases | Development agreement |
| 2016-01-07 | Glycotope (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-01-07 | Evotec (Germany) UCB (Belgium) | sample management | services contract | undisclosed | Services contract | |
| 2016-01-07 | 4D Molecular Therapeutics (USA - CA) Pfizer (USA - NY) | next-generation AAV vectors | cardiovascular diseases | collaboration - licensing | Cardiovascular diseases | Licensing agreement |
| 2016-01-06 | Ipsen (France) Galderma (Switzerland) | Dysport®/Azzalure® (botulinum toxin type A) | aesthetic indications | R&D development promotion distribution
|
Aesthetic medicine | Development agreement |
| 2016-01-06 | Enterome Bioscience (France) Takeda Pharmaceutical (Japan) | new therapeutics directed at microbiome targets | gastrointestinal diseases | collaboration R&D |
Gastrointestinal diseases - Digestive diseases | R&D agreement |
| 2016-01-06 | Spark Therapeutics (USA - PA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-01-05 | Sanofi (France) Mannkind Corporation (USA - CA) | Afrezza® (rapid-acting inhaled human insulin) | type 1 and type 2 diabetes | collaboration licensing manufacturing production |
Metabolic diseases | Termination of an agreement |
| 2016-01-05 | BMS (USA - NY) Oncodesign (France) | Nanocyclix®, oncology pharmacology models Predict®, Chi-mice® and Pharmimage® | collaboration |
Technology - Services - Cancer - Oncology | Collaboration agreement | |
| 2016-01-05 | Oxford Biomedica (UK) | resignation |
Rare diseases - Genetic diseases | Resignation | ||
| 2016-01-05 | Jacobs Engineering Group (USA - CA) Biogen (USA - MA) | construction of new premises services contract |
Technology - Services | Construction of new premises | ||
| 2016-01-05 | Blueprint Medicines (USA - MA) | nomination |
Nomination | |||
| 2016-01-05 | Genticel (France) | nomination |
Infectious diseases - Women health - Cancer - Oncology | Nomination | ||
| 2016-01-05 | Anthera Pharmaceuticals (USA - CA) | nomination |
Nomination | |||
| 2016-01-05 | Audentes Therapeutics (USA - CA) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-01-05 | Fuji Pharma (Japan) Chong Kun Dang Pharmaceutical (Republic of Korea) | biosimilar version of darbepoetin Alfa | renal anemia | licensing |
Kidney diseases - Renal diseases | Licensing agreement |
| 2016-01-04 | Immune Pharmaceuticals (USA - MA, Israel) Yissum (Israel) BioNanoSim (Israel) | nano-capsule formulation of cyclosporine A | atopic dermatitis, psoriasis | licensing |
Autoimmune diseases - Dermatological diseases - Inflammatory diseases | Licensing agreement |
| 2016-01-04 | Amag Pharmaceuticals (USA - MA) | nomination |
Nomination | |||
| 2016-01-04 | Baxalta (USA - IL) Symphogen (Denmark) | therapeutics against six checkpoint targets | R&D collaboration |
Cancer - Oncology | R&D agreement | |
| 2016-01-04 | Celyad (Belgium) | nomination |
Cancer - Oncology - Cardiovascular diseases - Regenerative medicine | Nomination |
